Sign In
Buy BNTX
$88.45
-0.690 (-0.774%)
At Close: Jun 03, 2026
BioNTech buys China's Biotheus to support oncology strategy
06:52am, Wednesday, 13'th Nov 2024
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on We
BioNTech to Acquire Biotheus to Boost Oncology Strategy
06:45am, Wednesday, 13'th Nov 2024
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquis
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
02:12pm, Saturday, 09'th Nov 2024
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
11:53am, Wednesday, 06'th Nov 2024
BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved reve
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
01:05pm, Monday, 04'th Nov 2024
BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-F
BioNTech surprises with Q3 profit driven by strong vaccine sales
11:48am, Monday, 04'th Nov 2024
BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-bas
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
09:41am, Monday, 04'th Nov 2024
On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
06:50am, Monday, 04'th Nov 2024
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
06:45am, Monday, 04'th Nov 2024
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET)
BioNTech to Host Innovation Series R&D Day on November 14, 2024
07:45am, Thursday, 31'st Oct 2024
MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. E
BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
01:11pm, Friday, 25'th Oct 2024
On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.
BioNTech's Oncology Gamble: High Stakes, Big Potential
08:00am, Monday, 21'st Oct 2024
BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outp
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
06:45am, Monday, 21'st Oct 2024
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, Novemb
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
05:50am, Tuesday, 08'th Oct 2024
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
BioNTech (BNTX) Presents at Innovation Series: AI Day
12:20pm, Thursday, 03'rd Oct 2024
BioNTech SE (NASDAQ:BNTX ) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ry
